Key Takeaways
- Shares of Hims & Hers Health (HIMS) tumbled approximately 7% Monday following the company’s announcement of a $300 million convertible notes offering.
- The convertible senior notes carry a maturity date of June 1, 2032, and will be sold privately to qualified institutional investors.
- Funds raised will support the company’s global expansion strategy, including its anticipated Eucalyptus acquisition targeted for mid-2026 completion.
- Part of the capital will be allocated toward capped call transactions designed to minimize dilution for existing Class A shareholders.
- The initial buyers received a 13-day option to purchase an additional $45 million worth of notes.
Shares of Hims & Hers Health (HIMS) experienced a significant decline of roughly 7% Monday after the telehealth platform revealed its intention to secure $300 million through an offering of convertible senior notes maturing in 2032.
Hims & Hers Health, Inc., HIMS
The decline began in premarket hours, with shares falling nearly 4% when news of the financing first emerged, and the downward pressure intensified after the opening bell.
The debt securities will be sold through a private placement to qualified institutional investors. Critical details including the interest rate, conversion ratio, and other fundamental terms remain to be determined at the time of pricing.
Interest payments on these notes will occur twice yearly. The notes reach maturity on June 1, 2032, subject to earlier repurchase, redemption, or conversion.
Bondholders will possess conversion rights under specified circumstances. Upon conversion, Hims & Hers retains the flexibility to fulfill obligations through cash payment, issuance of Class A common shares, or a combination thereof.
Strategic Use of Capped Calls for Shareholder Protection
The telehealth company intends to allocate a portion of the raised capital toward capped call transactions. This strategic move aims to mitigate potential equity dilution for current Class A shareholders in scenarios where noteholders convert their securities into stock.
The original purchasers secured an option valid for 13 days to acquire up to $45 million in additional notes. Should this option be fully exercised, total proceeds would reach $345 million.
The company gains the ability to redeem the notes beginning June 6, 2029 — though only under conditions where the Class A share price surpasses 130% of the conversion price for a specified duration. Additionally, noteholders possess the right to demand cash repurchase from the company if particular fundamental change events transpire.
Funding Global Growth and the Eucalyptus Transaction
According to Hims & Hers, the principal purpose of this capital raise centers on preserving financial flexibility to support its international expansion initiatives. This strategy prominently features the anticipated acquisition of Eucalyptus, a telehealth company based in Australia.
The Eucalyptus transaction is projected to reach completion by mid-2026. Complete financial details regarding the acquisition have not been publicly disclosed.
In addition to the acquisition, the company outlined plans to strengthen its technology infrastructure and fulfillment operations. Further investments will target enhanced AI capabilities and the development of its integrated data ecosystem.
HIMS shares were trading lower by approximately 7.7% Monday based on the most recent market data available.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
